Last 25.50 GBp
Change Today -0.25 / -0.97%
Volume 35.8K
TRX On Other Exchanges
As of 11:35 AM 09/17/14 All times are local (Market data is delayed by at least 15 minutes).

tissue regenix group plc (TRX) Snapshot

25.50 GBp
Previous Close
25.75 GBp
Day High
25.50 GBp
Day Low
25.50 GBp
52 Week High
02/26/14 - 32.13 GBp
52 Week Low
09/18/13 - 9.75 GBp
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TISSUE REGENIX GROUP PLC (TRX)

Related News

No related news articles were found.

tissue regenix group plc (TRX) Related Businessweek News

No Related Businessweek News Found

tissue regenix group plc (TRX) Details

Tissue Regenix Group Plc develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United Kingdom and the United States. Its dCELL technology comprises a patented process that removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold, which can be used to repair diseased or worn-out body parts. The company’s products include DermaPure, a dermis skin patch to cover chronic wounds; and porcine meniscus for implanting into the patient’s knee, which acts as a matrix to attract stem-cells and allow natural healing of damaged joints. It also offers heart valves to replace the patient’s own damaged valves, and provide a biological scaffold for population by patient's own cells; and vascular patches for peripheral vascular reconstruction in vascular surgery. The company serves wound care, cardiac, vascular, and orthopaedic markets. Tissue Regenix Group Plc is based in York, the United Kingdom.

48 Employees
Last Reported Date: 05/19/14

tissue regenix group plc (TRX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: 225.0K GBP
Executive Chairman
Total Annual Compensation: 100.0K GBP
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: 168.0K GBP
Compensation as of Fiscal Year 2014.

tissue regenix group plc (TRX) Key Developments

Tissue Regenix Receives Regulatory Approval to Start Meniscus Clinical Trial in the UK, Plus Updates on Dermapure US Commercialisation

Tissue Regenix Group plc announced that it has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), to start the first UK clinical trial of its dCELL® meniscal device to aid knee repairs. Following completion of final tests and preparations it is anticipated the trial will start in fourth quarter 2014. The trial approval marks a critical stage towards gaining EU clearance (and a CE Mark) which will enable full commercialisation of the dCELL® meniscus, and allow it to be used by clinics and doctors to help UK and European patients. Tissue Regenix's dCELL® meniscus will be used to repair damage from 'tears' in the meniscus knee cartilage as a result of acute injury or degeneration. Meniscal injuries affect around 1.5 million people per year in Europe and USA, and the dCELL® meniscus potentially addresses this substantial unmet clinical need. Designed to encourage tissue growth and regeneration the Tissue Regenix dCELL® meniscus aims to support the body's own physiological pathways for healing by providing a 3D matrix for cell adhesion and vascular ingrowth. The UK trial for the dCELL® meniscus will be conducted at The Hillingdon Hospitals NHS Foundation Trust, Uxbridge, The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust, Oswestry and at the Clifton Park Hospital, York.

Tissue Regenix Group Plc Announces Launch of DermaPure(TM) in the USA

Tissue Regenix Group plc announced that it has launched DermaPure ("DermaPure") its decellularised dermis product in the US. Tissue Regenix's partner CTS (Community Tissue Services) will begin shipping product to customers next week. In addition to the launch of DermaPure, the Group also announced that it has continued to expand its distribution network around the country and currently has a network of over 60 reps that covers 80% of the US. Through this network, sale representatives will actively promote Tissue Regenix's dCELL human dermis in acute care hospitals, Veteran Affairs (VA) Hospitals and institutions, as well as in Long Term Acute Care hospitals (LTACs). Furthermore, Tissue Regenix has also signed an exclusive government supplier partnership with TASSMA for the distribution of DermaPure. TASSMA provides business development services to medical device and equipment manufacturers seeking to rapidly grow their federal government market share. The partnership with TASSMA will allow Tissue Regenix to immediately target the Department of Veteran's Affairs Healthcare System and the numerous branches of the military. The commercial launch of the DermaPure dermis allograft will now allow Tissue Regenix to target a market worth $1.4 billion a year for wound healing devices and equipment. 6.5 million patients are afflicted by chronic wounds currently. Tissue Regenix's DermaPure works by taking human donor skin and removing the DNA and cells, using the patented dCELL(R) process to leave a natural biological scaffold that can be placed in the wound to aid natural healing by attracting the patient's own cells to the wound area. A trial in the UK has shown that patients who have had chronic wounds for an average of 4 1/2 years and who were treated with a single application of Tissue Regenix' DermaPure(TM) have seen an 87% reduction in the size of all wounds, while 60% of patients were completely healed, with virtually no recurrences. DermaPure can be easily administered in hospital and/or community settings, such as GP clinics, and is stored at room temperature, requiring no rehydration before use or expensive refrigerated storage.

Tissue Regenix Group Plc, Annual General Meeting, Jun 27, 2014

Tissue Regenix Group Plc, Annual General Meeting, Jun 27, 2014., at 10:00 GMT Standard Time. Location: DLA Piper UK LLP, Princes Exchange, Princes Square.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TRX:LN 25.50 GBp -0.25

TRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TRX.
View Industry Companies

Industry Analysis


Industry Average

Valuation TRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 26,757.9x
Price/Book 8.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 27,505.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TISSUE REGENIX GROUP PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at